Immunology

Lupus a tough disease to spot, treat

(HealthDay)—Lupus is difficult to diagnose and treat, but scientists are working to learn more about its genetic causes and to develop better treatments.

Arthritis & Rheumatism

Simultaneous diagnosis of SLE, pheochromocytoma described

(HealthDay)—A case of simultaneous diagnosis of systemic lupus erythematous (SLE) and pheochromocytoma, with disappearance of SLE after pheochromocytoma treatment, is described in a letter to the editor published online ...

Diseases, Conditions, Syndromes

Researchers identify enzyme that contributes to development of lupus

Researchers at Beth Israel Deaconess Medical Center (BIDMC) have identified an enzyme that is significantly elevated in mouse models of systemic lupus erythematosus and in blood samples of patients with lupus. Published online ...

Arthritis & Rheumatism

Monash researchers bringing hope to lupus patients

Researchers at Monash University are leading the world's largest study to describe lupus patients and disease characteristics, bringing treat-to-target options for lupus a step closer.

Arthritis & Rheumatism

SLICC/ACR criteria don't ID severe internal disease in SCLE

(HealthDay)—Neither the American College of Rheumatology (ACR) nor the Systemic Lupus International Collaborating Clinics (SLICC) criteria distinguishes patients with subacute cutaneous lupus erythematosus (SCLE) with major ...

Immunology

Study reveals role for oxidized mitochondrial DNA in lupus

Researchers at the Baylor Institute for Immunology Research have discovered that the neutrophils of systemic lupus erythematosus (SLE) patients release oxidized DNA from their mitochondria that can stimulate an unwanted immune ...

Immunology

Researchers find new clue in lupus autoantibody production

A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers ...

Oncology & Cancer

Treatment for lupus enters phase III

Lupuzor may become the first specific and non-immunosuppressant therapy for lupus, a disabling autoimmune disease that is currently incurable. Discovered by Sylviane Muller's team in the CNRS Immunopathologie et Chimie Thérapeutique ...

Immunology

Researchers answer long-standing question about lupus

For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other.

page 25 from 40